{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T09:47:20Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 25.6, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09502-6dd2-7c00-952d-40afa9608da0\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: fluticasone furoate\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 043: ", "usd": 0.0, "recall": true }, "codex": { "seconds": 81.2, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09502-6dc4-7c20-9fda-742559328d97\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: fluticasone furoate\nRegistry id: vr.tr.fluticasone-furoate\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this " } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:53:40+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:28+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q2166700", "registryId": "vr.tr.fluticasone-furoate", "name": "fluticasone furoate", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q2166700/", "model": { "registry_id": "vr.tr.fluticasone-furoate", "name": "fluticasone furoate", "purpose": "Enable an AI agent to identify fluticasone furoate, assess the quality and state of a material lot, and determine its suitability for a documented pharmaceutical or research use.", "definition": "Fluticasone furoate is a synthetic fluorinated corticosteroid and glucocorticoid receptor agonist used as an active pharmaceutical ingredient in intranasal and inhaled medicines to reduce inflammation.", "scope_statement": "This model owns the substance identity and material-state requirements of fluticasone furoate under vr.tr.fluticasone-furoate in PHY / PHY.MAT, including evidence needed to connect a qualified lot to downstream uses.", "in_scope": [ "Molecular identity, stereochemistry, identifiers and distinction from related fluticasone compounds", "Lot-specific assay, impurities, grade and analytical evidence", "Solid form, particle properties, solubility and stability under recorded conditions", "Substance-level pharmacological relationships and exposure constraints", "Handling classification, storage requirements and jurisdiction-specific substance records" ], "out_of_scope": [ "Finished nasal sprays, inhalation powders and combination medicines", "Inhaler devices, actuation performance and administration technique", "Patient diagnosis, prescribing, dosing and treatment monitoring", "Manufacturing process design and production equipment", "Independent models of fluticasone propionate, excipients or combination active ingredients" ], "distinguishing_features": [ "Require the molecular structure and stereochemistry associated with PubChem CID 9854489; a label saying only fluticasone is insufficient. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Fluticasone-Furoate)", "Distinguish its furoate ester from the propionate ester and from unesterified fluticasone; do not interpret furoate as a separate counterion. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Fluticasone-Furoate)", "Check the formula C27H29F3O6S and molar mass approximately 538.6 g/mol against structure-specific analytical evidence. [DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3e797fc-2636-49a0-b89e-5246b18ee440)", "Separate a lot of the active substance from a formulation containing it: product strength, excipients and delivery device do not establish bulk-substance identity or purity." ], "characteristics": [ { "name": "Structure-resolved identity", "kind": "category", "unit_or_values": "Stereochemical structure identifier; PubChem CID 9854489; independently verified CAS and other identifiers", "why_it_matters": "Prevents confusion among fluticasone derivatives and records with similar names." }, { "name": "Assay and reporting basis", "kind": "measurement", "unit_or_values": "% mass fraction; as-is, dried or solvent-free basis; method and uncertainty", "why_it_matters": "Makes lot potency interpretable without confusing chromatographic area percentage with substance content." }, { "name": "Related substances and residual contaminants", "kind": "measurement", "unit_or_values": "Individual and total impurities in % or ppm, with identities, detection limits and applicable specifications", "why_it_matters": "Determines whether a lot meets its intended-use requirements." }, { "name": "Solid-state identity", "kind": "state", "unit_or_values": "Observed crystalline or amorphous state; form designation; solvate or hydrate evidence; analytical method", "why_it_matters": "Allows changes in material behavior to be traced to physical form." }, { "name": "Particle-size distribution", "kind": "measurement", "unit_or_values": "D10, D50 and D90 in micrometres, with dispersion and measurement method", "why_it_matters": "Supports assessment of material intended for particle-sensitive formulations without claiming finished-device aerosol performance." }, { "name": "Condition-specific solubility", "kind": "measurement", "unit_or_values": "mg/mL or mol/L, with solvent, pH, temperature, solid form and equilibration protocol", "why_it_matters": "The label describes practical insolubility in water; quantitative values still require conditions and measurements. [DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3e797fc-2636-49a0-b89e-5246b18ee440)" }, { "name": "Thermal behavior", "kind": "measurement", "unit_or_values": "Transition or decomposition temperature in degrees Celsius, with method and atmosphere", "why_it_matters": "Distinguishes measured transitions from unsupported melting or boiling-point claims." }, { "name": "Lot disposition", "kind": "state", "unit_or_values": "Quarantined, released for specified use, rejected or awaiting reassessment", "why_it_matters": "Connects evidence to a permitted material-handling decision." }, { "name": "Pharmacological and metabolic relationships", "kind": "relation", "unit_or_values": "Glucocorticoid activity; CYP3A4-mediated metabolism; evidence linked to assay or product context", "why_it_matters": "Supports interpretation of activity and systemic-exposure concerns. [DailyMed](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3e797fc-2636-49a0-b89e-5246b18ee440)" }, { "name": "Handling and regulatory evidence", "kind": "relation", "unit_or_values": "Supplier SDS, jurisdiction, revision date, applicable hazard classification, exposure limit and substance registration", "why_it_matters": "Prevents unsupported transfer of one supplier's or jurisdiction's requirements to every lot." } ], "affordances": [ "Resolve a candidate material record to fluticasone furoate using structure and analytical evidence.", "Compare a lot's assay and impurity results with an explicitly selected intended-use specification.", "Assess whether particle and solid-state evidence supports a proposed formulation-development use.", "Flag storage excursions or analytical changes that require quarantine or reassessment.", "Link the substance to containing medicines while retaining product-specific route and authorization boundaries.", "Retrieve applicable handling controls and identify missing evidence before material use." ], "agent_conduct": { "may": [ "Explain fluticasone furoate as a corticosteroid in nasal and inhaled medicines, citing official labelling.", "Report approved indications, inhaler technique guidance and warnings from the label." ], "must_not": [ "Recommend, dose or adjust fluticasone furoate for a specific person.", "Advise stopping asthma or COPD controller medicine without a clinician.", "Present an inhaled steroid as a rescue medicine for acute attacks.", "Suggest sharing inhalers between people." ], "requires_human": [ "Changing a person's asthma, COPD or allergy treatment." ] }, "ethics": { "considerations": [ "Wrong inhaler advice can lead to life-threatening asthma attacks.", "Children on corticosteroids need growth and dose monitoring." ], "affected_parties": [ "People with asthma or COPD", "Children", "Prescribers and pharmacists" ] }, "owners": { "steward": "The prescriber and the pharmacist for each patient; medicines regulators authorize products.", "master_systems": [ "National medicines registers" ] }, "visual_identification": [ "Identified by product label, active ingredient name and pack details rather than by appearance alone." ], "failure_modes_and_hazards": [ "Oral thrush and voice changes with inhaled use.", "Nosebleeds with nasal use.", "Misuse as a rescue inhaler during attacks." ], "what_it_is_for": [ "Fluticasone furoate is encountered as an active ingredient in intranasal and inhaled medicines used to control inflammation.", "Pharmaceutical manufacturing and research laboratories examine its identity, purity and formulation suitability." ], "standards_and_regulation": [ "The Anatomical Therapeutic Chemical classification maintained by the WHO Collaborating Centre for Drug Statistics Methodology assigns fluticasone furoate code R01AD12 for nasal corticosteroid preparations." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q2166700: fluticasone furoate", "url": "https://www.wikidata.org/wiki/Q2166700", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Fluticasone furoate", "url": "https://en.wikipedia.org/wiki/Fluticasone_furoate", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "molecular-identity", "name": "Molecular identity", "description": "Establishes which fluticasone derivative the material represents.", "rationale": "Similar names must not collapse chemically distinct active substances into one identity.", "layers": [ { "id": "structure-and-identifiers", "name": "Structure and identifiers", "description": "Connects the registered thing to a stereochemically specified molecule.", "findings": [ { "id": "structure-backed-identification", "name": "Structure-backed identification", "description": "Identity should resolve to the structure recorded for fluticasone furoate, rather than relying on a supplier name alone. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Fluticasone-Furoate)", "questions": [ { "text": "Which stereochemical structure and identifiers define fluticasone furoate in this record?", "kind": "definition", "id": "structure-backed-identification-q01" }, { "text": "Which reference standard and analytical results establish that the supplied material matches that identity?", "kind": "provenance", "id": "structure-backed-identification-q02" } ] } ] }, { "id": "derivative-and-product-boundaries", "name": "Derivative and product boundaries", "description": "Separates the molecule from related compounds and containing medicines.", "findings": [ { "id": "furoate-specific-boundary", "name": "Furoate-specific boundary", "description": "Require explicit derivative identity and distinguish neat active substance from mixtures and finished products.", "questions": [ { "text": "What evidence excludes fluticasone propionate, unesterified fluticasone or an ambiguously named fluticasone material?", "kind": "boundary", "id": "furoate-specific-boundary-q01" }, { "text": "Does this record describe the active substance, a reference solution or a formulation containing other ingredients?", "kind": "boundary", "id": "furoate-specific-boundary-q02" } ] } ] } ] }, { "id": "lot-quality-and-grade", "name": "Lot quality and grade", "description": "Determines what a particular lot contains and which uses its evidence supports.", "rationale": "Correct molecular identity does not establish pharmaceutical suitability.", "layers": [ { "id": "assay-and-impurity-profile", "name": "Assay and impurity profile", "description": "Makes quantitative composition and its analytical basis inspectable.", "findings": [ { "id": "interpretable-composition-results", "name": "Interpretable composition results", "description": "Record assay separately from chromatographic purity, and preserve impurity identities, quantification limits and reporting bases.", "questions": [ { "text": "What is the fluticasone furoate assay, on which mass basis and by which validated method?", "kind": "measurement", "id": "interpretable-composition-results-q01" }, { "text": "Which related substances, residual solvents and other contaminants were measured, and against what limits?", "kind": "measurement", "id": "interpretable-composition-results-q02" } ] } ] }, { "id": "qualification-and-release", "name": "Qualification and release", "description": "Links lot evidence to an explicit material specification.", "findings": [ { "id": "use-specific-lot-disposition", "name": "Use-specific lot disposition", "description": "Treat grade and release as supported decisions for a specified use, rather than consequences of a vendor's purity claim.", "questions": [ { "text": "Which supplier, batch, certificate of analysis and specification revision establish this lot's provenance?", "kind": "provenance", "id": "use-specific-lot-disposition-q01" }, { "text": "Does the evidence support release for the proposed use, or is additional testing required?", "kind": "action", "id": "use-specific-lot-disposition-q02" } ] } ] } ] }, { "id": "physical-form-and-performance", "name": "Physical form and performance", "description": "Captures the solid and particle properties relevant to fluticasone furoate material behavior.", "rationale": "Substance identity alone cannot establish dissolution behavior or suitability for particle-sensitive formulations.", "layers": [ { "id": "solid-and-thermal-state", "name": "Solid and thermal state", "description": "Records observed physical form without assuming that every lot shares it.", "findings": [ { "id": "verified-solid-form", "name": "Verified solid form", "description": "Require analytical support for form assignments and distinguish melting, other transitions and decomposition.", "questions": [ { "text": "What diffraction, calorimetry or complementary evidence identifies this lot's crystalline or amorphous state?", "kind": "measurement", "id": "verified-solid-form-q01" }, { "text": "Which thermal events are observed, under what conditions, and how are they assigned?", "kind": "measurement", "id": "verified-solid-form-q02" } ] } ] }, { "id": "particles-and-solubility", "name": "Particles and solubility", "description": "Connects measured material properties to formulation-relevant questions.", "findings": [ { "id": "conditioned-material-performance", "name": "Conditioned material performance", "description": "Keep particle size, dissolution and equilibrium solubility distinct, and retain their measurement conditions.", "questions": [ { "text": "What particle-size distribution and agglomeration behavior are measured under a specified dispersion protocol?", "kind": "measurement", "id": "conditioned-material-performance-q01" }, { "text": "What solubility or dissolution results exist for the relevant medium, temperature and solid form?", "kind": "measurement", "id": "conditioned-material-performance-q02" }, { "text": "Which conclusions concern the substance particles, and which require testing of the finished formulation and device?", "kind": "boundary", "id": "conditioned-material-performance-q03" } ] } ] } ] }, { "id": "pharmacological-use-boundaries", "name": "Pharmacological use boundaries", "description": "Represents biological activity and exposure relationships while locating clinical decisions in product and patient models.", "rationale": "The same active substance can occur in products whose route, delivery and authorization differ.", "layers": [ { "id": "activity-and-exposure", "name": "Activity and exposure", "description": "Preserves the context of pharmacological and metabolic evidence.", "findings": [ { "id": "contextualized-biological-evidence", "name": "Contextualized biological evidence", "description": "Separate molecular activity from route-dependent exposure and retain the experimental context of each result.", "questions": [ { "text": "Which assays establish glucocorticoid activity, and what endpoints and comparators do they use?", "kind": "provenance", "id": "contextualized-biological-evidence-q01" }, { "text": "Which metabolism and interaction findings apply to fluticasone furoate, and in what exposure context?", "kind": "boundary", "id": "contextualized-biological-evidence-q02" } ] } ] }, { "id": "containing-medicine-relations", "name": "Containing medicine relations", "description": "Connects the active substance to product-specific evidence.", "findings": [ { "id": "route-and-combination-separation", "name": "Route and combination separation", "description": "Product links must carry their own route, formulation, companion ingredients and authorization evidence.", "questions": [ { "text": "Which verified products contain this substance, alone or with other active ingredients?", "kind": "provenance", "id": "route-and-combination-separation-q01" }, { "text": "Which suitability claims require a product-specific label instead of inference from the substance name?", "kind": "boundary", "id": "route-and-combination-separation-q02" } ] } ] } ] }, { "id": "stability-handling-and-controls", "name": "Stability, handling and controls", "description": "Supports evidence-based storage, reassessment and handling of fluticasone furoate lots.", "rationale": "A material can retain its name while its condition or permitted use changes.", "layers": [ { "id": "storage-and-degradation", "name": "Storage and degradation", "description": "Links actual storage history to validated material requirements.", "findings": [ { "id": "stability-supported-disposition", "name": "Stability-supported disposition", "description": "Use substance-lot stability evidence; finished-product storage instructions cannot automatically qualify bulk material.", "questions": [ { "text": "Which container, temperature, moisture and light conditions support the assigned retest period?", "kind": "provenance", "id": "stability-supported-disposition-q01" }, { "text": "Has an excursion or change in assay, impurities or solid form triggered quarantine or reassessment?", "kind": "action", "id": "stability-supported-disposition-q02" } ] } ] }, { "id": "hazards-and-jurisdiction", "name": "Hazards and jurisdiction", "description": "Distinguishes occupational handling evidence from therapeutic product warnings.", "findings": [ { "id": "documented-handling-controls", "name": "Documented handling controls", "description": "Require an applicable SDS and independently supported exposure controls; missing limits do not establish absence of hazard.", "questions": [ { "text": "Which current SDS, GHS classification and regulatory identifiers apply to this supplier's material and jurisdiction?", "kind": "provenance", "id": "documented-handling-controls-q01" }, { "text": "Is there an authoritative occupational exposure limit or a documented manufacturer-specific limit or band?", "kind": "measurement", "id": "documented-handling-controls-q02" }, { "text": "Which containment, protective equipment and waste procedures follow from the applicable evidence and task?", "kind": "action", "id": "documented-handling-controls-q03" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This is recalled information; no sources were consulted.", "Verify identifier records, solid-state properties, purity specifications and any applicable pharmacopoeial monographs before technical use.", "Check current local product labeling for approved uses, ages, strengths and safety details; no melting point, boiling point, exposure limit or GHS classification is asserted here." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of fluticasone furoate this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (INN)", "value_or_pattern": "fluticasone furoate", "note": "Names the active substance, not a particular finished medicine." }, { "scheme": "CAS Registry Number", "value_or_pattern": "397864-44-7", "note": "Identifies fluticasone furoate specifically." }, { "scheme": "Molecular formula", "value_or_pattern": "C27H29F3O6S", "note": "Describes elemental composition but does not uniquely identify stereochemistry." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of fluticasone furoate this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-standards-and-regulation", "name": "Standards and regulation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "United States FDA current good manufacturing practice requirements for finished pharmaceuticals, 21 CFR Parts 210 and 211, apply to medicines containing this substance.", "Approved indications, routes, strengths and age limits are governed by product-specific authorizations and labeling from regulators such as the FDA and relevant European authorities." ], "questions": [ { "id": "evidence-standards-and-regulation-q01", "text": "Which of these standards and regulation hold for the sense of fluticasone furoate this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Intranasal treatment of allergic rhinitis.", "Inhaled maintenance treatment of asthma, alone or in fixed combinations depending on the product and jurisdiction.", "Component of fixed-combination inhalers used for maintenance treatment of chronic obstructive pulmonary disease." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of fluticasone furoate this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Molar mass", "typical_range": "Approximately 538.58", "unit": "g/mol" }, { "quantity": "Physical state", "typical_range": "Solid at ordinary room temperature", "unit": "not applicable" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of fluticasone furoate this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Intranasal use can cause nosebleeds, local irritation and nasal ulceration.", "Inhaled use can cause oropharyngeal candidiasis and dysphonia.", "Systemic corticosteroid effects, including adrenal suppression, can occur, particularly with substantial exposure or interacting medicines.", "Strong CYP3A4 inhibitors can increase systemic exposure and the risk of corticosteroid adverse effects.", "Inhaled corticosteroid-containing treatment is associated with increased pneumonia risk in patients with chronic obstructive pulmonary disease." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of fluticasone furoate this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Brand names, prescription or nonprescription availability, approved ages and indications vary by jurisdiction.", "Available single-ingredient and combination formulations, strengths and delivery devices vary between markets." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of fluticasone furoate this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "Fluticasone propionate", "difference": "A distinct fluticasone ester with a propionate group instead of a furoate group; strengths and dosing are not interchangeable by mass." }, { "name": "Fluticasone", "difference": "The parent chemical structure; fluticasone furoate specifically contains the furoate ester." }, { "name": "Fluticasone furoate/vilanterol", "difference": "A medicine combining this corticosteroid with a long-acting beta2-adrenergic agonist, rather than the single chemical substance." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of fluticasone furoate this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which CAS, EC or alternative jurisdictional identifiers are verified against authoritative substance records, and which are absent or inapplicable?", "Which current compendial or manufacturer specifications define assay, stereochemical purity, related substances and residual-contaminant limits for each intended grade?", "Which solid forms are relevant to supplied material, and what validated particle-size and solubility data distinguish their intended uses?", "What measured thermal, degradation and bulk-storage data justify retest periods, and is a boiling-point value meaningful before decomposition?", "Which current supplier SDS classifications and authoritative or manufacturer-derived occupational exposure limits apply to bulk fluticasone furoate?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 18, "questions": 30 } }